InspireMD Inc (NSPR)

NASDAQ
Currency in USD
2.590
-0.010(-0.38%)
Closed·
After Hours
2.470-0.120(-4.633%)
·
NSPR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
2.5252.600
52 wk Range
1.8703.798
Key Statistics
Edit
Prev. Close
2.6
Open
2.6
Day's Range
2.525-2.6
52 wk Range
1.87-3.798
Volume
37.41K
Average Vol. (3m)
57.26K
1-Year Change
35.25%
Book Value / Share
1.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NSPR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.750
Upside
+83.40%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

InspireMD Inc Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.

InspireMD Inc Earnings Call Summary for Q4/2024

  • Q4 2024 revenue of $1.9M beat forecast; EPS loss of $0.19 slightly better than expected; stock rose 4.66% premarket
  • Full-year 2024 revenue up 13% YoY to $7M; gross margin declined to 24.1% from 28.7% in Q4 2023
  • CGuard Prime U.S. launch planned for H1 2025; potential $17.9M financing tranche upon FDA approval
  • Strong liquidity with $34.7M cash; analysts maintain "strong buy" with price targets $4.50-$5.00
  • SwitchGuard TCAR neuroprotection system approval targeted for H2 2026; company optimistic about U.S. market expansion
Last Updated: 03/12/2025, 09:07 AM
Read Full Transcript

Compare NSPR to Peers and Sector

Metrics to compare
NSPR
Peers
Sector
Relationship
P/E Ratio
−2.5x−2.9x−0.5x
PEG Ratio
−0.360.070.00
Price / Book
2.2x1.6x2.6x
Price / LTM Sales
11.3x3.4x2.9x
Upside (Analyst Target)
83.4%110.8%54.5%
Fair Value Upside
Unlock−3.1%8.5%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.750
(+83.40% Upside)

Earnings

Latest Release
Mar 12, 2025
EPS / Forecast
-0.19 / -0.20
Revenue / Forecast
1.95M / 1.83M
EPS Revisions
Last 90 days

People Also Watch

1.099
ZKIN
+7.75%
10.090
ORKA
-3.90%
1.793
IMRN
+4.18%
0.859
MOVE
-1.26%
2.792
XBIO
+3.60%

FAQ

What Is the InspireMD (NSPR) Stock Price Today?

The InspireMD stock price today is 2.59

What Stock Exchange Does InspireMD Trade On?

InspireMD is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for InspireMD?

The stock symbol for InspireMD is "NSPR."

What Is the InspireMD Market Cap?

As of today, InspireMD market cap is 79.35M.

What is InspireMD Earnings Per Share?

The InspireMD EPS is -0.76.

What Is the Next InspireMD Earnings Date?

InspireMD will release its next earnings report on Aug 12, 2025.

From a Technical Analysis Perspective, Is NSPR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.